Overview

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Status:
RECRUITING
Trial end date:
2028-07-31
Target enrollment:
Participant gender:
Summary
Prospective, interventional, open, randomized, national, multicenter, non-commercial trial
Phase:
PHASE2
Details
Lead Sponsor:
Anna Raciborska
Collaborator:
Wroclaw Medical University
Treatments:
naxitamab